Human vascular cell responses to the circulating bone hormone osteocalcin.
Sophie A MillarSusan I AndersonSaoirse E O'sullivanPublished in: Journal of cellular physiology (2019)
The purpose of this study was to characterize the direct effects of uncarboxylated osteocalcin (ucOCN) on vascular cell biology in vitro, to assess its potential function in pathophysiological conditions such as atherosclerosis. Human aortic endothelial cells (HAECs) and smooth muscle cells (HASMCs) were treated with ucOCN (0.1-50 ng/ml) and changes in phosphorylation of intracellular signaling proteins, angiogenesis, proliferation, migration, monolayer permeability, and protein secretion were measured. In HAECs, phosphorylated JNK and CREB were decreased with ucOCN (p < 0.05). In HASMCs, phosphorylated p70S6K and NF-ΚB were increased by ucOCN (p < 0.05). Cell proliferation increased in both cell types dose dependently which was blocked by AKT and ERK pathway inhibitors. ucOCN did not affect cell permeability, angiogenesis, or migration. The direct activity of ucOCN on vascular cells is recognized, particularly its proliferative effects. However, at least in physiological settings, it does not appear that osteocalcin may directly promote atherogenesis based on the outcomes measured.
Keyphrases
- endothelial cells
- signaling pathway
- cell proliferation
- single cell
- cell therapy
- induced apoptosis
- cardiovascular disease
- high glucose
- vascular endothelial growth factor
- pi k akt
- heart failure
- immune response
- metabolic syndrome
- weight loss
- mesenchymal stem cells
- bone mineral density
- postmenopausal women
- cell cycle arrest
- body composition
- small molecule
- adipose tissue
- binding protein
- protein kinase
- reactive oxygen species
- bone regeneration
- aortic dissection